Use your antibodies-online credentials, if available.
抗Human PALB2 抗体:
抗Mouse (Murine) PALB2 抗体:
抗Rat (Rattus) PALB2 抗体:
Human Polyclonal PALB2 Primary Antibody for ICC, IF - ABIN253057
Brough, Bajrami, Vatcheva, Natrajan, Reis-Filho, Lord, Ashworth: APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. in The EMBO journal 2012
Show all 2 Pubmed References
Human Polyclonal PALB2 Primary Antibody for IHC, IP - ABIN253058
Martrat, Maxwell, Tominaga, Porta-de-la-Riva, Bonifaci, Gómez-Baldó, Bogliolo, Lázaro, Blanco, Brunet, Aguilar, Fernández-Rodríguez, Seal, Renwick, Rahman, Kühl, Neveling, Schindler, Ramírez et al.: Exploring the link between MORF4L1 and risk of breast cancer. ... in Breast cancer research : BCR 2011
Human Polyclonal PALB2 Primary Antibody for EIA, WB - ABIN5555098
Loke, Pearlman, Upadhyay, Tesfa, Shao, Ostrer: Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway. in Human molecular genetics 2016
Our findings indicate that in the Indian population, there is a high prevalence of mutations in the high-risk breast cancer genes: BRCA1, BRCA2, TP53, and PALB2.
We identified a cluster of interacting genes involved in DNA repair that could be associated with predisposition to hereditary diffuse gastric cancer, in particular, PALB2.
The associations between five SNPs of PALB2 and breast cancer risk.
Our data presented the germline mutation status of PALB2 in Chinese breast cancer patients, suggesting that loss-of-function germline mutations of PALB2 are important in both familial and sporadic breast cancer. Clinically, these data may be helpful in genetic counseling of breast cancer patients with PALB2 germline mutation.
Truncating variants in PALB2, ATM and CHEK2 , but not XRCC2 were associated with increased breast cancer risk.
PALB2 associates with active genes through its major binding partner, MRG15, which recognizes histone H3 trimethylated at lysine 36 (H3K36me3) by the SETD2 methyltransferase
the involvement of PALB2 mutations in the predisposition to cancer and the role of PALB2 in stimulating error-free DNA repair through the FA/HR pathway.
FANCD2 and PALB2, as indicators of the upstream and downstream arms, respectively, colocalize independently of each other in response to DNA damage.
The findings demonstrate that RNF168 couples PALB2-dependent homologous recombination to H2A ubiquitylation to promote DNA repair and preserve genome integrity.
The results of the present study suggest that mutations in the PALB2 gene may be particularly relevant to breast cancer susceptibility in the Jamaican population.
We identified two PALB2 mutations that are founder alleles in Italian families, one of which is, independently, also a founder mutation in American-Hispanic breast cancers.
Our results indicate that the PALB2 exon 13 duplication is a pathogenic variant. The presence of the PALB2 duplication in the proband affected with high-grade serous ovarian cancer suggests that PALB2 might be associated with a predisposition to ovarian cancer.
We showed that the mutation frequency of RAD51C in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 mutation frequency in Japan might differ from that in Western countries
Study have shown that mutations in BRCA1, BRCA2, and PALB2 account for more than 10 % of breast cancer in Trinidad and Tobago. 25 different mutations identified; of these, four mutations were seen in two patients each.
Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish breast and/or ovarian cancer patients
Prevalence of germline PALB2 mutations among women with epithelial ovarian cancer in Ontario
inherited pathogenic variants in PALB2 were associated with high risks of breast cancer
Findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression.
In this paper, we describe an extension to the BOADICEA model to incorporate the effects of intermediate risk variants for breast cancer, specifically loss of function mutations in the three genes for which the evidence for association is clearest and the risk estimates most precise: PALB2, CHEK2 and ATM
Data show an increase of error-prone single-strand annealing (SSA) and microhomology-mediated end-joining (MMEJ) in the PALB2 (partner and localizer of BRCA2) c.1592delT mutation carriers.
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 heterozygosity .
results underscore the in vivo importance of the PALB2-BRCA1 complex formation in DSB repair and male meiosis
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
A key function for PALB2 is to interact with and to build up appropriate communication between BRCA1 and BRCA2.
This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2.
partner and localizer of BRCA2
, Fanconi N
, Fanconi anemia
, complementation group N
, partner and localizer of BRCA2-like